InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Opthea Files Notice of Annual General Meeting 16 Oct 2024 10:00AM $0.915 $0.013 fallen by 98.58%
$18 Opthea Wet AMD Program to be Presented at Innovate Retina 10 Oct 2024 8:42AM $0.870 $0.013 fallen by 98.51%
$18 Opthea Appoints Chief Medical and Chief Financial Officer 8 Oct 2024 8:51AM $0.895 $0.013 fallen by 98.55%
$18 Becoming a substantial holder 4 Oct 2024 8:16AM $0.825 $0.013 fallen by 98.42%
$18 Opthea to participate in UBS Virtual Ophthalmology Day 2024 1 Oct 2024 8:10AM $0.775 $0.013 fallen by 98.32%
$18 Opthea EURetina Symposium 2024 26 Sep 2024 7:05PM $0.790 $0.013 fallen by 98.35%
$18 Opthea Joins the S&P/ASX 300 Index 23 Sep 2024 8:31AM $0.710 $0.013 fallen by 98.17%
$18 Opthea Announces Completion of Drug Substance Campaign 19 Sep 2024 8:19AM $0.660 $0.013 fallen by 98.03%
$18 Opthea Presents at the 24th EURETINA Congress 11 Sep 2024 8:15AM $0.610 $0.013 fallen by 97.87%
$18 Opthea Corporate Presentation - September 2024 9 Sep 2024 8:32AM $0.535 $0.013 fallen by 97.57%
$18 S&P DJI Announces September 2024 Quarterly Rebalance 6 Sep 2024 5:10PM $0.535 $0.013 fallen by 97.57%
$18 Opthea Announces Executive Leadership Changes & Senior Hires 5 Sep 2024 8:26AM $0.550 $0.013 fallen by 97.64%
$18 Opthea presents at H.C.Wainwright 26th Investment Conference 4 Sep 2024 8:21AM $0.565 $0.013 fallen by 97.70%
$18 Opthea 2024 Corporate Governance Statement 30 Aug 2024 6:31PM $0.585 $0.013 fallen by 97.78%
$18 Opthea Reports Full-Year Results 30 Aug 2024 6:30PM $0.585 $0.013 fallen by 97.78%
$18 Opthea Preliminary Final and Annual Report 30 Aug 2024 6:24PM $0.585 $0.013 fallen by 97.78%
$18 Opthea to Participate in H.C Wainwright Virtual Conference 9 Aug 2024 8:16AM $0.415 $0.013 fallen by 96.87%
$18 Updated Quarterly Report and Cashflow 1 Aug 2024 4:13PM $0.445 $0.013 fallen by 97.08%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2024 10:17AM $0.420 $0.013 fallen by 96.90%
$18 Change in substantial holding 19 Jul 2024 5:12PM $0.380 $0.013 fallen by 96.58%
$18 Change in substantial holding 19 Jul 2024 8:18AM $0.380 $0.013 fallen by 96.58%
$18 Opthea Welcomes Retina Leaders to its Medical Advisory Board 18 Jul 2024 8:23AM $0.375 $0.013 fallen by 96.53%
$18 Security Class Reinstatement to Quotation- OPTOB 17 Jul 2024 7:05PM $0.375 $0.013 fallen by 96.53%
$18 OPTOB Top Holders 17 Jul 2024 12:13PM $0.375 $0.013 fallen by 96.53%
$18 OPTOB - Range of Units 17 Jul 2024 12:10PM $0.375 $0.013 fallen by 96.53%

126 - 150 of 733 results

Page 6 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.